In the second study, the incretin-based antihyperglycaemic agents liraglutide (a GLP-1 agonist) and vildagliptin (a dipeptidyl peptidase 4 [DPP-4] inhibitor) were shown to effectively ameliorate hyperglycaemia when co-administered with pasireotide [29]. Here, DPP4 is linked to Hyperglycemia.